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The Hepatic Sinusoid in Aging and 
Disease: Update and Advances From the 
20th Liver Sinusoid Meeting
Martí Ortega-Ribera ,1* Nicholas J. Hunt ,2,3* Jordi Gracia-Sancho ,1,4** and Victoria C. Cogger 2,3**
This is a meeting report of the 2019 Liver Sinusoid Meeting, 20th International Symposium on Cells of the Hepatic 
Sinusoid, held in Sydney, Australia, in September 2019. The meeting, which was organized by the International Society 
for Hepatic Sinusoidal Research, provided an update on the recent advances in the field of hepatic sinusoid cells 
in relation to cell biology, aging, and liver disease, with particular focus on the molecular and cellular targets involved 
in hepatic fibrosis, nonalcoholic hepatic steatohepatitis, alcoholic liver disease, hepatocellular carcinoma, and cirrhosis. 
In addition, the meeting highlighted the recent advances in regenerative medicine, targeted nanotechnologies, therapeu-
tics, and novel methodologies. (Hepatology Communications 2020;4:1087-1098).
The theme of the 2019 Liver Sinusoid Meeting (formerly known as the International Symposium on Cells of the Hepatic Sinusoid) 
was the role of the sinusoidal cells in disease and 
aging. This meeting discussed the advances in our 
understanding of the basic biology and pathobiology 
of sinusoidal cells: the liver sinusoidal endothelial cells 
(LSECs), hepatic stellate cells (HSCs), and Kupffer 
cells (KCs). Here, we report recent advances in their 
cell biology and how they contribute to the devel-
opment of multiple liver diseases, including hepatic 
fibrosis, nonalcoholic steatohepatitis (NASH), alco-
holic liver disease (ALD), hepatocellular carcinoma 
(HCC), and cirrhosis. One of the key messages from 
this conference is that these conditions may be tar-
geted with novel therapeutic agents. The advances in 
liver regeneration and aging along with the develop-
ment of innovative nanomedicines to target the liver 
cell types were also covered.
The symposium also honored the passing of one 
of our esteemed colleagues, Professor Soichi Kojima, 
from the RIKEN Center for Integrative Medical 
Sciences in Wako, Japan. His significant contributions 
to the study of the liver were remembered in a com-
memorative address by Professor Norifumi Kawada. 
The 20th Liver Sinusoid Meeting was cosponsored 
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by the Australian Ageing and Alzheimers Institute 
and received the endorsement of the European 
Association for the Study of the Liver and the Asia 
Pacific Association for the Study of the Liver.
LSECs
LSECs are unique among other endothelial cells in 
the body because they are characterized by transcellu-
lar pores known as fenestrae and the absence of a base-
ment membrane.(1,2) These pores allow bidirectional 
transfer of material between blood, HSCs, and hepato-
cytes. Functionally, the LSECs are antigen-presenting 
cells with roles in immune recognition, scavenging of 
waste-borne molecules by endocytosis, and regula-
tion of endothelial homeostasis by secretory materials, 
such as NO.(1) Stabilin-1 and stabilin-2 play a major 
role as waste scavenger receptors.(3,4) Edward Harris 
(University of Nebraska, Lincoln, NE) revealed a new 
role of stabilins as phosphorothioate antisense oligo-
nucleotide (PS-ASO) scavengers.(5) He demonstrated 
that injection of radiolabeled PS-ASOs in mice led 
to their accumulation in the liver, particularly within 
LSECs, through clathrin-dependent endocytosis.
It has been shown that the mannose receptor scav-
enging capacity is independent of the base macromol-
ecule but requires a glycosylated side chain.(1) Karen 
Sørensen (Arctic University of Tromsø, Tromsø, 
Norway) demonstrated that LSECs have a signifi-
cant reduction in scavenging of fluorescein isothiocy-
anate (FITC)-bovine serum albumin in a glycosylated 
lysosomal membrane protein (GLMP) knockout 
transgenic mouse model. This reduced scavenging was 
associated with increased liver collagen deposition. 
However, Glmpgt/gt(goldenticket) mice maintained 
the fenestrated cell surface, suggesting that main-
tenance of scavenger mechanisms and regulation of 
fenestrations are independently controlled.
Further examination of the mechanisms involved 
in endocytosis and fenestration formation were eval-
uated by multiple groups in response to treatments 
with branched-chain amino acids (BCAAs), free 
fatty acids (FFAs), glucocorticoids, and acetamin-
ophen, using in vitro and in vivo models. BCAA 
dietary imbalance leads to obesity and reduced life 
expectancy in mice.(6) Sun Woo Kang (University 
of Sydney, Sydney, Australia) demonstrated that a 
2-fold BCAA dietary imbalance reduced the fre-
quency of fenestrations but not their porosity or 
diameter. This effect was inhibited by caloric restric-
tion. Work by Karolina Szafranska (Arctic University 
of Tromsø)supported the detrimental effect of 
unbalanced BCAAs on LSEC morphology, showing 
reduced fenestration porosity and increased scaveng-
ing capacity. This group also presented on the ability 
of sildenafil and its analogues to increase porosity 
(confirming previous data(7,8)), without any alteration 
in endocytic capacity. Building on previous work 
demonstrating the toxic effects of palmitic acid (a 
FFA) on hepatic toxicity,(9) Yana Geng (University of 
Groningen, Groningen, the Netherlands) presented 
data on the toxicity of oleate and palmitate on in vitro 
rat LSECs. Each treatment alone induced necrosis; 
however, combination treatment did not induce cell 
death and led to increased lipid droplet formation. 
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It was hypothesized that lipid droplet formation is 
a protective mechanism that guards against FFA-
induced toxicity. Sabin Bhandari (Arctic University 
of Tromsø) shared some data on the in vitro effects 
of glucocorticoids in LSECs. Glucocorticoids are 
known to promote endothelial dysfunction, induce 
hepatic stenosis, and lead to insulin resistance in 
rats.(10,11) Proteomic analyses of LSECs after gluco-
corticoid treatment demonstrated down-regulation 
of major energy metabolism pathways and increased 
expression of proinflammatory cytokines and com-
ponents of redox systems 24  hours after treatment. 
Finally, Ingelin Kyrrestad (Arctic University of 
Tromsø) followed up published work on the neg-
ative impacts of high-dose acetaminophen(12) on 
in vitro-isolated LSECs. It was reported that 
high-dose acetaminophen treatment induces rapid 
dose-dependent impairment of LSEC redox poten-
tial, loss of endocytic capacity, and defenestration.
HSCs and Inflammation
HSCs are liver-residing pericytes involved in vita-
min A storage and the regulation of extracellular 
matrix metabolism.(7) Following insult, stimulation, or 
activation, HSCs are the main fibrogenic cells of the 
liver and contribute extensively to hepatic fibrosis.(13,14)
Grant Ramm (Queensland Institute of Medical 
Research, Berghofer Institute, Brisbane, Australia) 
gave a keynote address describing the recently iden-
tified role of heavy-chain ferritin as a novel damage- 
associated molecular pattern (DAMP) that activates 
nucleotide-binding oligomerization domain-like 
receptor family pyrin domain-containing 3 (NLRP3) 
inflammasome by intercellular adhesion molecule 
1, further driving HSC-derived interleukin (IL)-1β 
secretion.(15) Moreover, biomarker studies designed 
for the early detection of liver disease and staging 
of hepatic fibrosis revealed microRNA 25 (miRNA-
25) as an antifibrotic “brake” on HSC collagen syn-
thesis through the inhibition of regulators of Notch 
signaling/ span and suppression of transforming growth 
factor beta (TGF-β)-induced collagen synthesis.(16)
Novel data on the initiation step of HSC activation 
following loss of adherent junctions between HSCs and 
hepatocytes were presented by Hayato Urushima (Osaka 
City University, Osaka, Japan). Using immune-electron 
microscopy of an acute liver injury model (single CCl4 
injection), this group demonstrated that E-cadherin is 
a key adhesion molecule between HSCs and hepato-
cytes. Loss of these adherent junctions in the early 
stages of inflammation was followed by HSC activa-
tion and enhancement of the Yes-associated protein/ 
transcriptional coactivator with PDZ-binding motif 
(TAZ) expression. In vitro overexpression of TAZ in 
human HSCs up-regulated activation, whereas recon-
struction of E-cadherin-mediated adherent junctions 
led to TAZ suppression and HSC quiescence. This work 
adds to published work by this group in understanding 
the role of senescence HSCs in liver disease.(17)
In-depth characterization of the HSC activation 
pathway TGF-β1/mothers against decapentaple-
gic homolog (SMAD) was performed by Misako 
Sato-Matsubara (Osaka City University). Following 
previous studies on the role of cytoglobin in atten-
uating liver fibrosis in thioacetamide (TAA) mice,(18) 
Dr. Sato-Matsubara described the role of TGF-β in 
reactive oxygen species-induced DNA damage and 
demonstrated that TGF-β1 reduced cytoglobin, a free 
radical scavenger expressed uniquely in HSCs within 
the liver.(19) Further work showed that TGF-β1/
SMAD2 reduced cytoglobin in HSCs from patients 
with NASH through recruitment of Sp3 transcrip-
tion factor (SP3) and increasing alpha smooth mus-
cle actin (αSMA) expression through SMAD3. 
Following from this, Le Thi Thanh Thuy (Osaka 
City University) highlighted the effects of overexpres-
sion and knockout of cytoglobin. Within models of 
bile duct ligation, TAA-induced fibrosis, and dieth-
ylnitrosamine-induced liver cancer, it was shown that 
cytoglobin regulates HSC activation and suppresses 
inflammation in liver fibrosis and cancer.(18)
The key role that inflammatory pathways play in 
the development of liver diseases was highlighted 
by Frank Tacke (Charité Medical University, Berlin, 
Germany). In a recent review,(20) this group demon-
strated the importance of KCs and monocyte- 
derived macrophages (MoDMs) in health and disease. 
Analysis of single-cell RNA sequencing showed that 
the old dogma of M1 and M2 macrophages should 
be reconsidered in favor of a spectrum of activation 
states/functions.(20) This approach identified MoDMs 
as interesting targets for novel therapeutic approaches 
to immunomodulate the progression of liver dis-
ease.(20) In addition, Dr. Tacke’s group has devel-
oped expertise in intravital fluorescence microscopy 
(IVFM) for tracking, observing, and understanding 
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the role of macrophages in liver disease.(21) Finally, 
he demonstrated that within progressively worsening 
liver disease, KCs and MoDMs will respond to differ-
ent metabolic cues than in nondiseased states and may 
be critical targets for attenuating the progression of 
nonalcoholic fatty liver disease (NAFLD) and reduc-
ing cardiovascular risk.(16)
Liver Diseases
FiBRosis
Stiffening of the liver was originally understood 
to occur as the result of HSC activation, extracellular 
matrix deposition, and modulation of the liver angio-
architecture during fibrosis progression. This topic 
was a focus of research for several groups attending 
the meeting, which led to in-depth characterization 
and discussion of the effect of matrix stiffness on the 
modulation of sinusoidal cell phenotypes during the 
initial stages of liver disease.(22) Sergi Guixé-Muntet 
(Inselspital, Bern, Switzerland) reported the effect of 
stiffness on healthy primary cells by using collagen- 
coated tuned polyacrylamide gels with physiologi-
cally relevant stiffness (0.5  kPa as healthy, 13.5  kPa 
as fibrotic, and 30  kPa as cirrhotic). High stiffness 
induced cell dysfunction in all cell types. Hepatocytes 
demonstrated reduced albumin and urea synthesis, 
HSCs become activated with increased αSMA and 
collagen deposition, and LSECs were capillarized 
(loss of fenestrated surface) with reduced NO pro-
duction. Martí Ortega-Ribera (Institut d’Investiga-
cions Biomèdiques August Pi i Sunyer [IDIBAPS], 
Barcelona, Spain) highlighted the role of stiffness 
on primary cells isolated from cirrhotic livers and 
showed that culturing cells on soft substrates amelio-
rated the stiff-cell phenotype. Moreover, he showed 
that the antifibrotic drug liraglutide was effective in 
deactivating HSCs when cultured on stiff compared 
to softer matrices. As a molecular mechanism, high 
stiffness was associated with increased nuclear defor-
mation. Alleviating the nuclear–cytoskeleton tension 
was proposed as a strategy to recover nuclear spheric-
ity and cellular phenotype. Finally, Srivatsan Kidambi 
(University of Nebraska) recreated a fibrotic-like 
microenvironment using innovative, biomimetic, poly-
mer film-coated polydimethylsiloxane gels. This work 
indicated that LSECs cultured on these gels exhibited 
loss of fenestrations, impaired hyaluronic acid endocy-
tosis, and increased expression of cell adhesion mole-
cules. Overall, these findings suggest a leading role of 
matrix stiffness in deregulating sinusoidal cells during 
liver disease progression.
nasH
Jean-François Dufour’s presentation (Inselspital) 
described the contribution of hepatic endothelial 
dysfunction to poor health outcomes in patients 
with NASH. Professor Dufour has previously out-
lined the therapeutic approaches for the treatment of 
NASH,(23) and in this lecture he updated the dele-
gates on the current understanding of the role of sinu-
soidal cells in NASH.(24,25) Sinusoidal endothelial 
dysfunction precedes inflammatory and fibrotic pro-
gression in liver disease.(24) Of note, the loss of NO 
release from the endothelium contributes to increased 
intrahepatic resistance and activation of HSCs.(24) 
Targeting of cells expressing endothelial dysfunction 
markers, such as vascular adhesion-factor 1, with 
antifibrotic and inflammatory drugs may reduce the 
migration of immune cells to the liver and limit liver 
disease progression.(25) Other presented therapeutic 
approaches focused on targeting LSECs to resolve 
NASH. Miren Bravo (Vall d’Hebron Institut de 
Recerca [VHIR], Barcelona, Spain) presented data 
on the role of statins in restoring the LSEC pheno-
type and reducing portal pressure in a rat model of 
NASH without fibrosis.(26) NASH animals exhibited 
increased portal pressure, mainly due to endothe-
lial dysfunction (decreased phosphorylated protein 
kinase B and phosphorylated endothelial nitric oxide 
synthase [NOS], increased endothelin 1 [ET-1] lev-
els, and a higher predominance of dedifferentiated 
cluster of differentiation [CD]32b− LSECs). HSCs 
from these animals had reduced vitamin A storage 
and displayed activation of ET-1 downstream signal-
ing. Treatment with statins resulted in a reduction 
in portal pressure levels, NASH reversion, and sig-
nificant recovery of LSEC morphology, leading to a 
more quiescent phenotype of HSCs.(26)
Finally, the involvement of the role of runt-related 
transcription factor 1 (RUNX1) in NASH by clin-
ical, in vitro, and in vivo studies was presented by 
Savneet Kaur (Institute of Liver and Biliary Sciences 
[ILBS], New Delhi, India).(27) This group found that 
messenger RNA and protein expression of RUNX1 
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was enhanced in patients with NASH (correlating 
with disease severity) and colocalized with vascular 
endothelial growth factor receptor 3 (VEGFR3)+ 
LSECs and CD45+ liver-infiltrating macrophages. 
Knockdown approaches using nanolipocarriers con-
taining RUNX1 small interfering RNA (siRNA) 
in steatotic LSECs (>50%) resulted in substantial 
down-regulation of angiogenic, inflammatory, and 
adhesion gene expression with decreased infiltration 
of dendritic and T cells in the liver. In vivo, silencing 
of RUNX1 markedly reduced CD45+CD3+ liver- 
infiltrating lymphocytes and CD11c+ dendritic cells 
in both infiltrating and circulating lymphocytes.(27)
alD
In ALD, the innate immune system contributes 
significantly to liver damage.(28) KCs and peripheral 
blood mononucleocytes are critical to this process 
because they become sensitized to bacterial lipopoly-
saccharides and elevate proinflammatory cytokines. 
Adam Kim (Cleveland Clinic, Cleveland, OH) pre-
sented next-generation sequencing data to under-
stand why innate immune cells become hypersensitive 
to lipopolysaccharide. In response to chronic alcohol 
exposure, KCs are sensitized to activation by pathogen- 
associated molecular patterns and DAMPs, and this 
leads to a state of chronic inflammation in the liver 
through expression of tumor necrosis factor alpha, 
IL-6, IL-8, and IL-18; this chronic inflammation 
contributes to the progression of ALD through reac-
tive oxygen species imbalance.(29)
From a different perspective, Kenichi Ikejima 
( Juntendo University, Tokyo, Japan) presented recent 
data on the alterations in small intestine microbiota 
following chronic ethanol feeding in obese KK-Ay 
mice and the actions of rifaximin, an antibiotic 
used to treat irritable bowel syndrome and hepatic 
encephalopathy, on ethanol-induced liver injury. This 
group found that ethanol administration led to an 
Erysipelotrichales abundance of microbiota, with rifax-
imin reversing this abundance and preventing hepatic 
steatosis in this obese mice model.(30)
HCC
Advances in biomarkers and therapeutics tar-
geting the Wnt/β-catenin pathway in HCC were 
reported at the meeting. This pathway is involved 
in the epigenetic development of HCC and pro-
gression to metastasis.(31,32) The identification of a 
potential surrogate biomarker of sex determining 
region Y-box 9 (Sox9) in HCC was presented by 
Kristy Chan (University of Hong Kong, Hong Kong, 
China). Sox9 confers “stemness” properties in HCC 
through the Wnt/β-catenin pathway.(33) This group 
showed the correlation between Sox9+ HCC and 
the serum marker clusterin. The involvement of the 
Wnt/β-catenin pathway in HCC was also examined 
by Nuria Guerrero-Celis (Universidad Autónoma 
de México, Mexico City, Mexico) who investigated 
the use of an adenosine-derivative compound (IFC-
305) as an HCC therapeutic. This group reported 
that IFC-305 reduced cell survival in HCC cell 
lines but did not impair survival of a human hepatic 
progenitor cell line.(34)
CiRRHosis
The etiology, association with vascular disease, 
and treatment of cirrhosis was one of the key areas 
of interest at this meeting. In his lecture on vascu-
lar changes in liver disease, Jaime Bosch (Inselspital) 
discussed the similarities between the pathobiology 
of cirrhosis and the changes seen in the endothe-
lial wall in atherosclerosis, postulating that cirrhosis 
should be considered a vascular disease of the liver. 
Cirrhotic liver shows marked vascular distortion, 
stiffness, and irregular capillarized sinusoids.(35) 
The endothelium of cirrhotic livers is profoundly 
dysfunctional,(14) becoming proangiogenic, proin-
flammatory, prothrombotic, and provasoconstrictive, 
with a striking resemblance to the changes seen in 
atherosclerosis, such as increased perfusion pressure 
and sensitivity to vasoconstrictors, together with 
markedly impaired vasorelaxation mechanisms.(36,37) 
Overall, this suggests that these factors contribute 
to the development of portal hypertension through 
increased resistance to blood flow and vascular 
tone.(35,38)
The individual cells of the sinusoid undergo phe-
notypic changes during liver disease progression to 
cirrhosis. LSECs become capillarized, lose their pro-
tective NO regulation, and undergo immune cell infil-
tration(39); HSCs become activated, proliferative, and 
fibrogenic(40); and KCs become activated and proin-
flammatory with engorgement, similarly to systemic 
macrophages.(20) A recent advance in the transcriptome 
Hepatology CommuniCations, July 2020ORTEGA-RIBERA, HUNT, ET AL.
1092
of LSECs during the progression of cirrhosis was pre-
sented by Anabel Fernández-Iglesias (IDIBAPS). The 
progression of capillarization was observed in LSECs 
isolated from rats after undergoing 2, 6, or 14 weeks of 
CCl4 treatment. She found that 7,349 genes were dys-
regulated in LSECs isolated from the acute liver injury 
model (2  weeks of CCl4). These genes were related 
to inflammation and cell-to-cell interaction pathways. 
Fibrotic LSECs (6 weeks of CCl4) had 6,989 dysreg-
ulated genes, which were primarily involved in cell 
proliferation and development, including angiogene-
sis and vascular proliferation. Finally, cirrhotic LSECs 
(14 weeks of CCl4) exhibited 4,069 dysregulated genes 
implicated in cell transformation and invasion and 
tumor development. Complex transcriptomic analysis 
highlighted similarities between capillarization of rat 
LSECs and primary human cirrhotic LSECs.
In addition, advancements in our understanding 
of posttranslational modifications in CCl4 animal 
models and patients with liver fibrosis were pre-
sented by Natalia Nieto (University of Chicago, 
Chicago, IL). Dr. Nieto’s group has identified a post-
translational signature of the oxidant stress sensate 
high-mobility group box 1 (HMGB-1) isoforms that 
may be measured in animal models and patients.(41) 
Interestingly, their mass spectrometry-based method 
could potentially be used to stage clinical liver fibro-
sis progression and measure therapeutic responses. 
HMGB-1 is a DAMP that is increased in expression 
by hepatocytes and KCs following CCl4 treatment. 
HMGB-1 binds to the receptor for advanced gly-
cation end products on HSCs, leading to its activa-
tion and increased collagen deposition.(41) Recently, 
this group demonstrated that ablation of HMGB-1 
in intestinal epithelial cells reduced diet-induced 
NASH in mice.(42)
The role of LSECs in phagocytic and adapta-
tive T-cell responses following CCl4-induced cir-
rhosis was discussed by Rubén Francés (Miguel 
Hernández University, Alicante, Spain). The innate 
immune response is directed in part by the activity 
of LSECs,(43) suggesting an increased phagocytic 
role for LSECs in cirrhosis. Escherichia coli challenge 
(intraperitoneally delivered, 24 hours before) activated 
toll-like receptors, integrins, members of the comple-
ment cascade, and regulatory molecules, such as liver 
and lymph node sinusoidal endothelial cell C-type 
lectin, in both KCs and LSECs, suggesting increased 
LSEC phagocytic activity.(44)
Multiple presented studies highlighted the potential 
of LSECs and HSCs as therapeutic targets in cirrho-
sis, using animal models. The therapeutic regression 
of cirrhosis by using vasoactive compounds, such as 
statins,(36) cyclic guanosine monophosphate activa-
tors/enhancers,(45) and strong antioxidants,(46,47) is all 
mediated through changes in LSECs and HSCs.(48) 
Balasubramaniyan Vairappan ( Jawaharlal Institute 
of Postgraduate Medical Education and Research, 
Pondicherry, India) demonstrated in CCl4-induced 
animal models that the severity of portal hyperten-
sion was associated with increased expression of NOS 
trafficking inducer (NOSTRIN), with candesar-
tan cilexetil treatment (angiotensin II type 1 recep-
tor antagonist) reducing NOSTRIN and increasing 
NO. Similarly, Denise van der Graaff (University 
of Antwerp, Antwerp, Belgium) presented her work 
on intrahepatic vascular resistance in rats fed a 
choline-deficient diet. This study demonstrated that 
angiotensin II and cyclooxygenase 2 receptor antago-
nists mitigated the increased pressure gradient in this 
animal model. Chang-Peng Zhu (Second Military 
University, Shanghai, China) presented work using 
TAA and CCl4 animal models to examine the role 
of serotonin and its receptor 1A in portal hyperten-
sion. Serotonin receptor 1A demonstrated a critical 
role in hepatic hemodynamics, with agonist treatment 
promoting increased portal pressure and antagonism 
reducing portal pressure by increased NO. Finally, 
Zhi-Ren Liu (Georgia State University, Atlanta, GA) 
presented work on ProAgio treatment, which induced 
apoptosis in integrin αvβ3-expressing cells. This pro-
moted depletion in activated HSCs and capillarized 
LSECs, with significant improvements in hepatic 
fibrosis.(49) These integrin receptors are heavily 
expressed in the endothelium, macrophages, and acti-
vated HSCs in experimental animal models.(50)
HSCs targeting pathways were demonstrated by 
Dinesh Mani Tripathi (ILBS). Dr. Tripathi high-
lighted orphan nuclear receptor subfamily 4, group A, 
member 1 (NR4A1) as a novel modulator of the HSC 
pathogenic phenotype. Increased NR4A1 expression is 
observed in patients with cirrhosis, CCl4- and TAA-
treated rats, and in vitro-activated HSCs. Other ther-
apeutic pathways discussed were farnesoid X receptor 
(FXR) agonists, peroxisome proliferator-activated 
receptor agonists, and caspase inhibitors, all related 
to regression of cirrhosis through actions on hepato-
cytes.(47,51-53) Clinically, statins, FXR agonists, and 
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obeticholic acid have demonstrated positive results in 
patients with cirrhosis.(54,55)
Liver Regeneration
One of the most remarkable aspects of the liver is 
its ability to regenerate following acute injury, partial 
hepatectomy (pHx), and administration of damaging 
chemicals.(56) Following acute injury and pHx, the 
liver regenerates to “hepatostat,” the ideal size ratio 
to maintain body homeostasis. This process is heav-
ily dependent on progenitor cells and cellular plas-
ticity. Anna Mae Diehl (Duke University, Durham, 
NC) described the unique resilience that enables 
the liver to regenerate by the Hedgehog (Hh) sig-
naling pathway after pHx. Cellular plasticity in the 
liver uses similar pathways between organogenesis 
and regeneration centralized around up-regulation of 
Hh signaling ligands.(57) In development, Hh signal-
ing controls progenitor fate and tissue construction, 
whereas in adults, it regulates progenitor responses, 
matrix remodeling, and proliferation of hepatocytes 
and ductular cells.(57) This demonstrates that the 
mechanisms of liver organogenesis are retained with 
age and promote reconstruction following injury 
as long as there is a stimulus.(57) The Hh signaling 
pathway is a complex regulated transducer that may 
be a potential therapeutic target to regulate the liver’s 
response to injury, particularly because it is involved in 
liver regeneration, chronic liver disease, and HCC.(58) 
Activation of these pathways drives progressive loss 
of hepatocytes, leading to accumulation of fibrogenic 
cells and culminating in fibrosis and cirrhosis; target-
ing these pathways is a therapeutic area worth further 
investigation.(57,59,60)
Understanding gene expression and signaling path-
ways following pHx was discussed by Nur Raman 
(Uniersiti Sains Islam Malaysia, Kuala Lumpur, 
Malaysia). Using germ-free mice, this group demon-
strated that intestinal microbiota drive liver regen-
eration, with a delayed response seen in germ-free 
animals. Superb three-dimensional image-based 
reconstruction of the liver microarchitecture follow-
ing pHx was presented by Rajanikanth Vadigepalli 
(Thomas Jefferson University, Philadelphia, PA). This 
work advanced the group’s previous studies examining 
miRNA expression dynamics(61) and demonstrated 
the chronology of cellular vascular and biliary growth 
in liver regeneration. Remodeling involved the forma-
tion of a temporary dense bile canalization network 
that regressed following regeneration. In contrast, the 
sinusoidal networks maintained a branched structure 
in full contact with hepatocytes throughout the two 
distinct stages of regeneration.
Takayo Yanagawa (Tokai University, Tokyo, Japan) 
demonstrated that crosstalk between blood cells and 
hepatocytes during liver regeneration is mediated 
by opioid growth factor receptor like-1 (OGFRL1), 
suggesting that OGFRL1-expressing cells may be 
an important potential regenerative therapy. Finally, 
an additional regenerative therapy was presented by 
Shunhei Yamashina ( Juntendo University) showing 
that liver regeneration following pHx occurs by a 
cathepsin L inhibitor in CCl4-induced fibrotic livers. 
The group observed that their inhibitor Z-Phe- 
Tyr-aldehyde accelerated liver regeneration when 
given intraperitoneally for 3 days.(62,63)
The Aging Liver
Building on the work delivered at the previous 
International Society for Hepatic Sinusoidal Research 
(ISHSR) conferences,(64) Professors Le Couteur, 
McCourt, and Török presented on the advancements 
made in the understanding of the aging liver, methods 
of viewing this process, and age-related components 
of accelerated fibrosis.
The aging liver undergoes the seven hallmarks of 
aging, leading to defenestration of LSECs, accumula-
tion of lipid droplets and collagen deposition in HSCs, 
low-grade activation and inflammation by KCs, and 
cellular senescence and reactive oxygen species imbal-
ance in hepatocytes.(65-67) These changes contribute to 
poor liver function with advancing age in a clinical set-
ting.(67,68) Mashani Mohamad (Universiti Teknologi 
Majlis Amanah Rakyat, Selangor, Malaysia) built on 
her published data(69) and further demonstrated how 
age-related and diabetes-induced defenestration of 
LSECs contributed to changes in circulating lipo-
proteins and hepatic insulin sensitivity. Therapeutic 
targets for age-related changes in LSECs have been 
shown with multiple agents that target either the 
VEGF/NO pathway or the nutrient-sensing pathways 
through adenosine monophosphate-activated pro-
tein kinase/nicotinamide adenine dinucleotide.(70,71) 
The limitation of using these agents is the broad 
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off-target effects; David Le Couteur (University of 
Sydney) presented novel data on targeting individual 
cell types in the liver by using orally administrated 
nanomedicines.(72)
Visualization of age-related defenestration has to 
date been limited to electron microscopy and fixed-cell 
super-resolution microscopy techniques.(73) However, 
impressive data derived from direct stochastic opti-
cal reconstruction, structured illumination, atomic 
force, and stimulated emission depletion microscopy 
presented by Peter McCourt (Arctic University of 
Tromsø) demonstrated that it is possible to stain and 
visualize the LSECs as they move between defenes-
trated, fenestrated, and ultrafenestrated states.(8,74) 
These techniques allow for the effects of therapeutic 
agents on the ultrastructure of LSECs to be viewed in 
real time.(8,67)
With age, there is an accelerated development of 
fibrosis in the liver.(66,75) Natalie Török (Stanford 
University, Sacramento, CA) presented data on the 
age-related changes in 52  kDa isoform Src homol-
ogy 2 domain containing (p52Shc) in the liver and 
its contribution to accelerated fibrosis in aging. 
p52Shc is the human homolog of the adaptor protein 
SHC-1 that has been shown to modulate lifespan and 
the stress response by targeting insulin/insulin-like 
growth factor 1 and c-Jun N-terminal kinases signal-
ing pathways in Caenorhabditis elegans.(76) Professor 
Török demonstrated that p52Shc-mediated activa-
tion of phagocyte oxidase (p47phox)/nicotinamide 
adenine dinucleotide phosphate oxidase 2 (NOX2) 
leads to heightened redox stress, exacerbates inflam-
matory responses, and accelerates fibrotic progression 
in animal models. This finding is particularly import-
ant because dysregulation of redox pathways occurs 
within aging hepatocytes(65,67) and directly contributes 
to liver fibrosis.(77) Therapeutic targeting of this path-
way is applicable to both age-related and liver disease 
progression given that the NOX pathway promotes 
cellular injury, impairs hepatic microcirculation, and 
contributes to NAFLD progression.(78)
Nanomedicines
Current approaches for ameliorating liver diseases 
are focused on deactivating HSCs. However, inter-
action between LSECs and HSCs provides a unique 
cellular target for therapies. The development of new 
techniques to target drug/material delivery to LSECs 
has become a research focus. In the first approach, 
Nicholas Hunt (University of Sydney) described silver 
sulfide quantum dots (QDs; 8  nm in diameter) for 
in vivo-targeted delivery to LSECs.(70,72) These orally 
administrated QDs are rapidly transferred across the 
small intestine and taken up by the liver (75% of 
ingested material within 30  minutes). They do not 
enter systemic circulation, are cleared by hepatobili-
ary excretion within 24 hours, and do not demonstrate 
hepatic toxicity or immunorecognition. When coated 
with a formaldehyde-treated bovine serum albumin 
biopolymer, improved liver targeting and enhanced 
LSEC localization occur. Coupling of metformin to 
these QDs increased the bioavailability of this drug 
5-fold in the liver and 50-fold in LSECs.(72)
A second targeting approach was presented by 
Diana Hide (VHIR) who provided data on polymeric 
micelles (22.4  nm in diameter) that were rapidly 
internalized by healthy LSECs and HSCs in vitro. 
Although LSECs isolated from cirrhotic rats main-
tained their internalization capacity, this was dramat-
ically reduced in HSCs. Validation experiments were 
performed with encapsulation of simvastatin (entrap-
ment efficiency >96%), showing fewer toxic effects 
than the nonencapsulated drug and an improved phe-
notype of LSECs and HSCs isolated from bile duct 
ligation animals (Krüppel-like factor 2 up-regulation 
and increased fenestrae and porosity). Polymeric 
micelles administered to animals intravenously were 
found in the liver (40% accumulation) in both healthy 
and cirrhotic animals.
Finally, Bård Smedsrød (Arctic University of Tromsø) 
demonstrated the uptake of nanocrystals in liver cells. 
Two different formulations (1,2-distearoyl-sn-glycero- 
3-phosphoethanolamine-N-[amino(polyethylene 
glycol)-200 [DSPE-PEG200] and Pluronic F-127) 
were investigated with or without polyvinylpyrroli-
done K30/aerosol OT and administered in vitro or by 
intravenous injection in mice. In vivo, the particles dis-
tributed primarily into hepatocytes, while in vitro they 
were mainly found in LSECs or KCs. DSPE-PEG200 
outperformed Pluronic F-127.
Methods
Methodological advances in hepatic sinusoi-
dal research range from novel animal models to 
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cellular isolations and microscopy techniques. The use 
of animal models to study liver diseases was widely 
addressed by Francisco Javier Cubero (Complutense 
University, Madrid, Spain). Although most animal 
models of liver diseases are very useful for elucidat-
ing pathophysiology, some only partially represent the 
characteristics of human liver diseases.(79,80) Therefore, 
special caution needs to be taken when selecting the 
most suitable animal model for a given purpose.
Advances in hepatic sinusoidal hemodynamics and 
IVFM techniques were presented by Antony Wheatley 
(National University of Ireland, Galway, Ireland). 
This group has shown that changes that occur in the 
hepatic microcirculation under physiological circum-
stances (e.g., homeostasis or liver regeneration)(81) 
following acute liver injury (e.g., ischemia-reperfusion 
injury)(82) or chronic liver disease are important to the 
understanding of the whole pathophysiological pro-
cess. With widefield IVFM, this process can be visu-
alized using FITC-labeled dextran or erythrocytes to 
assess intrahepatic blood flow, rhodamine-6G to visu-
alize rolling and adhering of white blood cells, nuclear 
stain Hoechst 33362 to identify normal or apoptotic 
hepatocytes, and vitamin A-related autofluorescence 
to identify HSCs.
A novel human LSEC isolation and characteriza-
tion method was presented by Pantelitsa Papakyriacou 
(University of Birmingham, Birmingham, United 
Kingdom). After finely slicing livers, Dr. Papakyriacou 
adjusted enzymatic digestion according to the tex-
ture of the tissue (increased time for cirrhotic livers). 
Cell isolation was enhanced by gradient centrifuga-
tion, followed by immunomagnetic selection. Isolated 
LSECs were cultured in endothelial cell media with 
human serum, VEGF, and hepatocyte growth factor. 
Immunohistochemistry analysis from healthy livers 
showed high type II Fc gamma receptor (FcγRII2) 
and low CD31+ expression, whereas cirrhotic livers 
exhibited low FcγRII2 and high CD31+ staining, con-
firming pseudocapillarization during cirrhosis.
Fig. 1. Summary overview of the recent discoveries presented at the 20th Liver Sinusoid Meeting. The diagram summarizes the main 
topics discussed, including the physiology of LSECs, HSCs, and KCs and their contribution to the development of multiple liver diseases 
(fibrosis, NASH, ALD, HCC, and cirrhosis). In addition, advances in liver regeneration and aging along with the development of novel 
methods and sinusoidal-targeted nanomedicines were covered at this meeting. Abbreviations: miR, micro RNA; mRNA-Seq, messenger 
RNA sequencing; PAMP, pathogen-associated molecular pattern.
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Anett Larsen (Arctic University of Tromsø) stud-
ied the autofluorescence of adult human LSECs. 
This work showed lysosomal lipofuscin autofluores-
cence may impede fluorescent-based techniques and 
the use of TrueBlack as a lipofuscin autofluorescence 
quencher. In vitro cultures revealed a time-dependent 
reduction of autofluorescence with TrueBlack in the 
ultraviolet spectrum with traces of autofluorescence 
remaining in the red and far-red channels.
Robin Fraser (University of Otago, Christchurch, 
New Zealand) presented on the health implications of 
the use of surfactants (dimethylnitrosamine [DMNA] 
and Poloxamer 407) in industry and agriculture. 
DMNA was banned; however, Poloxamer 407 is still 
widely used. These surfactants are used as defenes-
trating agents.(83) The development of liver diseases is 
highly prevalent in animal models and, given livestock 
exposure to these materials, it is suggested that liver 
function tests should be employed for animals.
Conclusions
This meeting discussed the advances in our under-
standing of the basic biology and pathobiology of the 
cells of the sinusoid. We described the advancements 
in our understanding of LSEC endocytosis and fen-
estration regulation, HSC activation pathways, the 
contribution of stiffness to fibrotic cellular pheno-
types, endothelial dysfunction in NASH and ALD, 
Wnt/β-catenin pathways in HCC, vascular dysfunc-
tion in cirrhosis and how this can be targeted with 
novel therapeutics, Hh signaling as a key regulator of 
liver plasticity, super-resolution microscopy of aging 
cells, nanomedicine development for targeting liver 
diseases, and finally, the recent progress in liver disease 
methodologies (Fig. 1). The symposium again demon-
strated that research on cells of the hepatic sinusoid is 
flourishing. The 21st Liver Sinusoid Meeting will be 
held in Shanghai, China, in September 2021. Please 
check the ISHSR website (www.ishsr.net) for further 
information. See you in Shanghai in 2021!
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